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Abstract
Background:Weaimed toverify safety andeffectivenessof certoparin real-worlduseand to identify predictorsof thromboembolic events
or bleeding. Methods: This was a non-interventional study documenting patients at hospital- or office-based physicians. Results: Patients’
(n¼ 1407) mean age was 53.7 + 16.1 years. Reason for certoparin use was prophylaxis of venous thromboembolism in 1331 (94.6%)
patients and treatment in 76 (5.4%) patients. In only 11.4% of those receiving prophylaxis and 13.2% of those receiving treatment dosing,
duration and schedule of certoparin were within label. There were 2 patients with deep venous thrombosis ([DVT], no pulmonary embo-
lism [PE]), and 51 patients (3.8%) with minor (nonmajor) bleeding complications in patients receiving prophylaxis. Two patients treated
with certoparin had recurrent DVT and one had PE (one patient with minor bleeding). Conclusions: Certoparin is very effective in real
world. This also applies to patients in whom clinical decision making leads to an alteration of recommended application.
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Introduction
Certoparin is registered for the prophylaxis and treatment of
venous thromboembolism (VTE) in Germany. For this purpose,
the recommendation is to use a dose of 3000 IU for a mean of 7 to
10 days for peri- and postoperative prophylaxis, 9 to 20 days in
nonsurgical patients and 12 to 16 days in patients with stroke.
For the treatment of VTE, a twice daily application of 8000 IU
for 10 to 14 days is recommended. The registration further
names a number of comorbid disease conditions and concomi-
tant pharmacotherapy that may interfere with the efficacy and
safety of certoparin and have to be considered when making a
treatment decision to balance benefits and risks.
Because we found no data on a comparison of the recom-
mended use of certoparin as to the summary of product charac-
teristics (SPC) with real-world treatment decisions, we
conducted a non-interventional study on office- or hospital-
based physicians working in general-, orthopedic-, or trauma
surgery, and on cardiologists. To identify predictors and spe-
cific real-world situations in which the balance between bene-
fits and risk may be suboptimal, we captured patient
characteristics, data on actual certoparin use, and the frequency
of thromboembolic or bleeding complications in 1407 patients.
Within this context, there were a number of predefined
objectives: (1) to determine the incidence of symptomatic
thromboembolic events; (2) to determine the incidence of
major bleeding complications; (3) to describe use of certoparin
preparations, dosing, and duration of treatment in different
indications and its comparison with SPC; and (4) to assess




The PROMEMBER (Prospektive, nicht-interventionelle Studie
zu Mono-Embolex in der Thromboseprophylaxe und Therapie)
was a non-interventional, noncontrolled, prospective study in
patients receiving the low-molecular-weight heparin certoparin
for the prophylaxis or treatment of thromboembolic events.
Patients were included by office- or hospital-based physicians
working in general-, orthopedic-, or trauma surgery, or
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cardiology. The study was conducted in accordance with the
German Medicines Law (§ 67 (6) Arzneimittelgesetz). Ethical
approval was obtained by the ethics committee of the Univer-
sity of Ulm on May 22, 2009 and patients had to provide writ-
ten informed consent.
Patients
Patients of either gender were eligible for inclusion into the
study if they were at least 18 years old and the physician had
selected certoparin for preventing or treating thromboembolic
events. Patients were included on a consecutive basis per center
involved aiming at largely preventing a selection bias. No other
in- or exclusion criteria applied.
Documentation
Patients were documented at the start (baseline) and at the end
of certoparin use. The following variables were collected at
baseline: patient characteristics (year of birth, gender, body
weight and height, relevant concomitant treatment, and smok-
ing status), expositional and dispositional risk factors, labora-
tory parameters (hemoglobin, hematocrit, platelets, serum
creatinine, activated partial thromboplastin time [aPTT], inter-
national normalized ratio [INR], D-dimer, and anti-factor Xa),
and the reason, timing, duration, and dose of prophylaxis or
treatment. These variables were collected based on physician
assessment and, in the case of comorbidities and risk factors,
not objectively verified. Interventions were classified as
abdominal- (abdominal interventions only), general- (varicosis,
hernia, thyroid gland surgery, etc), neuro-, orthopedic-, or other
surgery or because of a medical reason. At the end of certoparin
use, symptomatic thromboembolic events and their mode of
verification, the Wells criteria for deep venous thrombosis
(DVT)/pulmonary embolism (PE), laboratory parameters
(aPTT, INR, and anti Xa), as well as bleeding complications,
heparin-induced thrombocytopenia, thrombocytopenia, and
adverse events were documented. Finally, there was an
optional photo documentation of the site of the surgical inter-
vention (not reported in the current manuscript).
Statistics
This was a non-interventional epidemiologic study with a
descriptive analysis. To estimate the number of patients to be
included, we defined that we would like to observe adverse events
with an incidence of 0.05% with a power of 80%, resulting in
3000 patients to be included by 300 physicians (10 patients each).
SPSS for Windows (release 18.0) was used for the statisti-
cal analysis. For categorical data, absolute and relative fre-
quencies and for continuous variables, means with standard
deviations or medians with quartiles were calculated. Contin-
uous variables were tested according to Kolmogorov-Smirnov
for normal distribution. Differences were tested for signifi-
cance with the Student t test and the Mann-Whitney U test
in case of 2 independent, normally distributed samples. In
case of more than 2 independent, non-normally distributed
samples, the Kruskal-Wallis H test was employed. Categori-
cal data were evaluated with the chi-square test or the Fisher
exact test. For correlations, Spearman rho was determined.
Multivariable analysis was done employing binary logistic
regression analyses with forward inclusion using likelihood
ratio criteria (P  .05).
Results
After the inclusion of 1407 patients, the study was stopped prema-
ture because of slow recruitment. Patients had a mean age of 53.7
+ 16.1 years (range 18-95 years), 50.4% being male and 23.4%
smokers were included through 244 physician offices into this
non-interventional study between September 16, 2009 and Febru-
ary 28, 2010. Patients had a mean body weight of 80.1+ 15.2 kg
and a body mass index (BMI) of 27.0 + 4.6 kg/m2. Of these,
75.8% had dispositional risk factors, 49.2% expositional risk fac-
tors, and about half of patients reported to receive comedication
potentially interfering with coagulation. In this study, we found
factor V Leiden mutation in 3 patients (42.9%), hyperhomocys-
teinemia in 1 patient (14.3%), protein C deficiency in 1 patient
(14.3%), antiphospholipid syndrome in 1 patient (14.3%), and
other not specified defect in 1 patient (14.3%). Overall, we found
7 (100.0%) molecular thombophilias.
The reason for the initiation of certoparin was the prophy-
laxis of VTE in 1331 patients (94.6%) and the treatment of
VTE in 76 (5.4%).
Certoparin for VTE Prophylaxis
A total of 1331 patients received certoparin prophylaxis
because of orthopedic surgery (50.2%), general surgery
(22.2%), and abdominal surgery (3.6%). A total of 24% of
patients had other including nonsurgical reasons for prophy-
laxis. Anamnestic trauma or surgical intervention within the
last 12 weeks (25.2%), obesity (22.0%), varicosis (20.1%), and
age  70 years (13.5%) were the most frequent dispositional
risk factors. Of all, 50.4% had expositional risk factors such
as a surgical intervention >1 hour (23.8%); 21.5% received
nonsteroidal anti-inflammatory drugs (NSAIDs; Table 1).
The mean duration of certoparin prophylaxis was 14.1 +
16.5 days (Figure 1). Prophylaxis was started at a mean of
4.5 + 8.2 hours before surgery (median 1 hour) and reintro-
duced at a mean of 13.0 + 12.0 hours after the intervention.
The majority of patients (n ¼ 1203; 90.4%) received the
3000 IU prophylactic dose of certoparin. Of all, 9.6% received
a higher dose (>3000 IU), 39.6% and 25.6% for a reduced dura-
tion in surgical and nonsurgical patients, respectively (Table 2).
A total of 2 patients had confirmed thromboembolic events
(DVT no PE) despite certoparin prophylaxis. Both patients
underwent orthopedic surgery. With regard to the Wells score,
the criteria of edema, pain, swelling of the lower leg, and sur-
gical intervention <12 weeks—each of them—were found in
50% of the patients. None of these patients received further
investigations to verify the findings. Two patients had an
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ischemic stroke (Table 3). While there was no case of major
bleeding, 51 patients (3.8%) had any minor bleeding
complication. None of the 7 contemplated patients with throm-
bophilia had bleeding complications.
Certoparin for VTE Treatment
A total of 76 patients received certoparin treatment because of
DVT (n¼ 75) and PE (n¼ 2); 1 patient had both DVT and PE.
A history of VTE (44.7%), obesity (34.2%), aged  70 years
(32.9%), and varicosis (19.7%) were the most frequent disposi-
tional risk factors, stroke was the most frequent expositional
risk factor (15.8%). Of all, 15.8% received platelet inhibitors
as concomitant pharmacotherapy (Table 1).
The mean treatment duration was 14.1+ 16.5 days (median 9
days and maximum 163 days). Treatment was initiated at a mean
of 4.5 + 8.6 hours (the majority of which <3 hours) after first
diagnosis and a maximum of 48 hours. Of all, 50% of patients
(n ¼ 38) received a half-therapeutic dose of 8000 IU and 50% a
full-therapeutic dose of 2 8000 IU. Of all, 26.3% received treat-
ment for duration of less than 10 days (Table 2).
Two patients had confirmed recurrent DVT and one PE. With
regard to the Wells score, the criteria of edema was found in 50%
of the patients. Of all, 50% received duplex sonography and 50%
Table 1. Patients Characteristics and Risk Factors in PROMEMBER (Expositional and Dispositional) for Thrombosis
Prophylaxis
(n ¼ 1331; 94.6%)
Treatment
(n ¼ 76; 5.4%)
Age, mean + SD (years) 53.2 + 16.0 63.4 + 14.8
Body weight, mean + SD (kg) 79.8 + 15.2 84.8 + 14.6
BMI, mean + SD (kg/m2) 26.8 + 4.6 29.0 + 4.8
Male gender (%) 50.2 53.9
Smokers (%) 24.0 11.8
Dispositional risk factors n % n %
History of VTE 63 4.7 34 44.7
Thrombophilia 1 0.1 6 7.9
Neoplasia 26 1.9 11 14.5
Age 70 years 180 13.5 25 32.9
Chronic heart failure 71 5.3 3 3.9
Chronic respiratory insufficiency 10 0.8 0 0.0
Obesity (BMI >29 kg/m2) 293 22.0 26 34.2
Immobilization/paresis 122 9.2 6 7.9
Trauma or surgical intervention <12 weeks 336 25.2 9 11.8
Contraception/hormonal therapy 89 6.7 2 2.6
Chronic inflammatory disease 16 1.2 3 3.9
Mechanical heart valve 5 0.4 0 0.0
Pregnancy, postpartum, section 3 0.2 0 0.0
Polyglobuly 2 0.2 0 0.0
Thrombocytosis 2 0.2 1 1.3
Nephrotic syndrome 2 0.2 1 1.3
Varicosis 268 20.1 15 19.7
Rheumatism 33 2.5 1 1.3
Inflammatory bowel disease 10 0.8 0 0.0
Others 70 5.3 5 6.6
Any 1006 75.6 72 94.7
Expositional risk factors
Stroke 30 2.3 2 2.7
Myocardial infarction 32 2.4 1 1.3
Immobilization (nonsurgical) 19 1.4 5 6.6
Central venous catheter 5 0.4 2 2.6
Systemic infection 7 0.5 0 0.0
Surgical intervention 317 23.8 4 5.3
Exsiccosis 9 0.7 1 1.3
Others 252 18.9 5 6.6
Any 630 47.3 19 25.0
Concomitant pharmacotherapy
Platelet inhibitors 88 6.6 12 15.8
Anticoagulants 43 3.2 6 7.9
NSAIDs 286 21.5 6 7.9
Others 134 10.1 11 14.5
Abbreviations: BMI, body mass index; NSAIDs, nonsteroidal anti-inflammatory drugs; SD, standard deviation; VTE, venous thromboembolism.
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received compression ultrasound. The patient with both DVT and
PE received lung scintigraphy. Of the 76 patients, 1 had minor
bleeding complications (none major; Table 3).
Predictor Analysis for Minor Bleeding Complications
Upon univariable analysis of all 1407 patients for risk factors
influencing the risk of (minor) bleeding, we identified a BMI
<29 kg/m2 (odds ratio [OR] 2.858), NSAID use (OR 3.477),
and major surgery >1 hour (OR 3.827) to predict bleeding
complications (Figure 2). In a multivariable analysis, the
association with NSAID use (P ¼ .001) and major surgery
>1 hour (P ¼ .006) remained significant and a hematocrit at
baseline lesser than or equal to the median became significant
(P ¼ .039).
Discussion
The present analysis of 1407 patients receiving certoparin for
the prophylaxis or treatment of VTE demonstrates that there
is a difference between the patient population studied and the
dosing or duration used in clinical trials (determining the rec-
ommendation in the SPC) as compared to a real-world situa-
tion. This may be exemplified by the high proportion of
patients with concomitant medication interfering with coagula-
tion (which is not forbidden by the SPC but warrants caution
and is much higher in real world than in clinical trials), the high
proportion of surgical patients receiving less than 7 days of cer-
toparin prophylaxis (39.6%), and the quarter of nonsurgical
patients receiving less than 9 days of prophylaxis (25.6%).
On the other hand, prophylaxis is prolonged (beyond the SPC
defined treatment duration) in a substantial proportion of
patients which is appropriate as to the guidelines1 has been
demonstrated to be effective for certoparin in surgical patients2
but is not covered by the label of certoparin. Against this back-
ground, it is reassuring for clinicians to see that thromboem-
bolic events are the exception (2 patients with DVT of 1331
patients) and that there were only minor bleeding complica-
tions (51 of 1331 patients).
Table 2. Certoparin Preparations, Dosing, and Duration of Prophylaxis and Treatmenta
Below Recommended Above
Prophylaxis
Dosing of certoparin (n ¼ 1331) <3000 IU 3000 IU >3000 IU
n (%) 0 (0.0) 1203 (90.4) 128 (9.6)
Duration of certoparin prophylaxis
Duration of prophylaxis in surgery (n ¼ 1122) <7 d 7-10 d >10 d
n (%) 444 (39.6) 351 (31.3) 327 (29.1)
Duration of prophylaxis in nonsurgical patients (n ¼ 207) <9 d 9-20 d >20 d
n (%) 53 (25.6) 74 (35.7) 80 (38.6)
Duration in pts after stroke (n ¼ 2) <12 d 12-16 d >16 d
n (%) 2 (100.0) 0 (0.0) 0 (0.0)
Dosing schedule
Last dose prior surgery (n ¼ 1331) <1 h 1-2 h >2 h
n (%) 649 (48.8) 374 (28.1) 308 (21.9)
First dose after surgery (n ¼ 1331) <12 h 12-24 h >24 h
n (%) 777 (58.4) 509 (38.2) 45 (3.4)
Treatment
Dosing of certoparin (n ¼ 76) <2  8000 IU 2  8000 IU >2  8000 IU
n (%) 38 (50.0) 38 (50.0) 0 (0.0)
Duration of treatment (n ¼ 76) <10 d 10-14 d >14 d
n (%) 20 (26.3) 25 (32.9) 31 (40.8)
a11.4% of patients had a recommended dosing, duration, and schedule of certoparin prophylaxis throughout; 13.2% of patients had a recommended dosing and
duration of certoparin treatment throughout.
Figure 1. Duration of prophylaxis depending of the surgical field.
Interventions were classified as general- (varicosis, hernia, thyroid gland
surgery, etc), abdominal- (abdominal interventions only), neuro-,
orthopedic-, or other surgery or because of a medical reason. Boxes
illustrate medians with interquartile distance (median; 25/75 percentile),
lines include all values (minimum to maximum). Outliers are illustrated
as circles (1.5-3 length of the box) or stars (>3 the box length).
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Clinical Effectiveness of Certoparin Prophylaxis
The efficacy of certoparin to prevent VTE has been documen-
ted for patients undergoing orthopedic surgery, where the rates
of thromboses ranged from 10% to 32%,2-4 abdominal surgery
(0.0% and 10.8%5-8), and ambulatory interventions (arthro-
scopy; 0% and 0.15%9,10). Against this background, we docu-
mented 2 patients with VTE corresponding to 0.15% and this is
compatible with the later reports mostly in ambulatory
patients.6,7,9,10
There are a number of aspects that might put into perspec-
tive the low thrombosis rates seen in our study. First, the patient
population in PROMEMBER was very heterogeneous because
patients were recruited in the hospital as well as in the ambula-
tory setting. Second, the interventions covered a range from
trauma surgery to less invasive procedures such as arthroscopy
or coronary interventions. Third, we only documented sympto-
matic thromboembolic events and performed no systematic
evaluation with respect to asymptomatic events as has been the
case in controlled trials. Taken together, this might implicate
that we have documented a lower bound estimate of the true
event rate in a mixed population given that we had less severe
interventions and partially asymptomatic events.
Rates of any bleeding in clinical studies ranged around
3.4%.6 There were no major bleeding complications in our doc-
umentation but 3.8% had minor bleeding.
Clinical Effectiveness of Certoparin Treatment
The evaluation of certoparin for the treatment of VTE in PRO-
MEMBER is limited when the less number of patients were
included (n ¼ 76). These patients were older, had a higher
BMI, and a considerable risk of VTE. Two of these patients had
recurrent DVT (2.6%), 1 patient PE (1.3%), and 1 patient had
minor bleeding (1.3%; no major bleeding). Thromboembolic
event rates were higher than results of the EASTERN study,
in which no patients out of 273 had a recurrent thrombosis with
certoparin.11 Bleeding rates were low compared with prior
randomized controlled trials as the one by Harenberg in which
3.5% of 893 patients with acute symptomatic proximal DVT
had major bleeding.12 It was also low compared with a prior
study in 11 LMWH-treated patients where 1.5% experience
major bleeding.13 However, the results have to be considered
with caution. The total patient number results in a wide confi-
dence interval and thus, the true event rates might differ consid-
erably. Further 50% of patients received a reduced dose of
<2  8000 IU and 26.3% had their certoparin applied for less
than the recommended duration of 10 to 14 days.
Real-World Use of Certoparin
A further important finding from PROMEMBER is that a sub-
stantial proportion of patients receiving certoparin for the prophy-
laxis or treatment of thromboembolic events in real world were
not treated within the recommendations of the current labeling.
When conducting a predictor analysis for the occurrence of
any bleeding complications, we identified major surgery >1
hour and NSAID use to be associated to an increased risk.
While prolonged major surgery usually cannot be avoided, this
is less so for NSAIDs (ibuprofen, etc) which might be tempo-
rarily discontinued when anticoagulation becomes necessary.
Actual certoparin dosing and duration of prophylaxis were
different in real world than in the SPC with about 10% of
patients receiving higher than recommended doses, 25% to
40% receiving less than recommended duration, and 30% to
39% receiving a prolonged prophylaxis. This is likely based
on the physician’s assessment as to the type of intervention/sur-
gery and the assumed thromboembolic risk: patients receiving
a reduced duration of prophylaxis might have undergone less
severe interventions (such as arthroscopy) and one might
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Figure 2. Predictors of bleeding complications (only patients with
minor bleeding were considered because there was no patient with
major bleeding). Odds ratios with confidence intervals >1 that, for
example, NSAID use confers a higher risk of bleeding complications
than no NSAID use; **from binary logistic regression analysis for
which only 292 of 1407 patients were available; BMI indicates body
mass index; NSAID, nonsteroidal anti-inflammatory drugs; ULN,
upper limit of normal; OR, odds ratio; CI, confidence interval.
Table 3. Thromboembolic Events and Bleeding Complications
Total
n %
Prophylaxis (n ¼ 1331)
Deep venous thrombosis (DVT) 2 0.2
Pulmonary embolism (PE) 0 0.0
Major bleeding complications 0 0.0
Minor bleeding complications 51 3.8
Ischemic stroke 2 0.2
Treatment (n ¼ 67)
Deep venous thrombosis (DVT) 2 2.6
Pulmonary embolism (PE) 1 1.3
Major bleeding complications 0 0.0
Minor bleeding complications 1 1.3
Any cardiovascular eventa 0 0.0
aTwo patients had ischemic stroke.
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question whether or not the particular patient should have
received any prophylaxis. On the other hand, a prolonged pro-
phylaxis (30%-39% of patients) has been, while not being cov-
ered by the labeling, documented to be effective in clinical
studies2 and recommended in current guidelines1 because of
the persistently elevated thromboembolic risk.
Limitations
PROMEMBER is a prospective, non-interventional study on
the real-world use of certoparin in daily practice. It benefits
from a large patient number although initial recruitment targets
were no met. It does, however, have limitations inherent to
many real-world studies, for example, no perfect completeness
of patient data, the potential of unknown bias, no control group,
and no end point validation. While these limitations may quan-
titatively influence the results, we expect no qualitative
changes. Whether or not patients with thrombophilia are any
different than other patients cannot be answered from the pres-
ent data set because 95% confidence intervals are wide and
overlap with each other.
On the other hand, the real-world approach allows to inves-
tigate issues such as compliance of use with indications that are
not possible in more stringent study designs such as rando-
mized controlled trials.
Conclusion
Taken together, it appears that certoparin, used for the prophy-
laxis and treatment of thromboembolic events, is very effective
in a real-world situation. This finding is even more important
because it also applies to patients in whom clinical decision
making leads to an alteration of the recommended dosing
schedule.
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